When will the FDA approve Compass Pathways' COMP360 Psilocybin?
As of Tue, 20 Oct 2026 11:11:57 UTC, Kalshi traders price Before 2028 (89.0%), Before October 2027 (87.0%), Before July 2027 (84.0%). The market has $24K in volume and closes on Sat, 01 Jan 2028.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before 2028 | 89.0% | 89.0¢ | 11.0¢ |
| Before October 2027 | 87.0% | 87.0¢ | 13.0¢ |
| Before July 2027 | 84.0% | 84.0¢ | 16.0¢ |
| Before Mar 1, 2027 | 62.0% | 62.0¢ | 38.0¢ |
| Before Jan 1, 2027 | 23.0% | 23.0¢ | 77.0¢ |
Market details
- Venue: Kalshi
- Volume: $24K
- Liquidity: $24K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before 2028:
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Sources
Related markets
- How many launches will SpaceX have in September?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- How many launches will SpaceX have in October?
- When will any company achieve AGI?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.